PHILADELPHIA — (June 21, 2022) — Due to the development of resistance to chemotherapy and recurring tumors, patients with ovarian cancer often have low survival rates. Therefore, new therapeutic opti…
PHILADELPHIA — (June 16, 2022) —The Wistar Institute, an international biomedical research leader in cancer, immunology and infectious disease, announces its Bold Science // Global Impact Capital Cam…
PHILADELPHIA — (JUNE 14, 2022) — The National Advisory Committee of the Pew Scholars Program in the Biomedical Sciences, has chosen Amelia Escolano, Ph.D., Assistant Professor in The Wistar Institute…
PHILADELPHIA — (March 8, 2022) — The Wistar Institute announces that Ronald Caplan, founder and president of PMC Property Group, Inc., and his wife Ellen have donated $10 million to Wistar’s prestigi…
PHILADELPHIA — (Feb. 4, 2022) — Nearly four decades after its discovery, HIV has killed 36.3 million people, with no vaccine in sight. However, a new study by researchers at The Wistar Institute, an…
PHILADELPHIA — (Feb. 1, 2022) — The first generation of COVID-19 vaccines have been highly effective, but also have limitations: their efficacy can wane without a booster shot, and they may be less e…
Wistar is a finalist of the STEM Talent Challenge to create a new life science workforce training program to address Pennsylvania industry growth and demand for skilled workers. U.S. Assistant Secret…
PHILADELPHIA — (Jan. 17, 2022) — A new study by researchers at The Wistar Institute, an international biomedical research leader in cancer, immunology, infectious disease, and vaccine development, ha…
PHILADELPHIA — (Jan. 5, 2022) — The Wistar Institute announces the initiation of a Phase 2 clinical study of VK-2019 in patients with advanced Epstein-Barr Virus (EBV)-positive nasopharyngeal carcino…
PHILADELPHIA — (Dec. 2, 2021) — Fox Chase Cancer Center has opened an investigator-initiated, phase 1 clinical trial to evaluate the safety and efficacy of gamitrinib in patients with advanced cancer…
